Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review
| Autor: | Luca Sala, Davide Seminati, Maddalena Mancin, Paolo Bidoli, Diego Cortinovis, Alessia Pastore, Andrea Alberti |
|---|---|
| Přispěvatelé: | Sala, L, Mancin, M, Pastore, A, Seminati, D, Cortinovis, D, Bidoli, P, Alberti, A |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty medicine.drug_class EGFR Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Osimertinib Progression-free survival Epidermal growth factor receptor Aplastic anemia Lung cancer biology business.industry medicine.disease respiratory tract diseases 030104 developmental biology Tolerability 030220 oncology & carcinogenesis biology.protein Adenocarcinoma business |
| Zdroj: | Lung Cancer. 142:120-122 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2020.02.019 |
| Popis: | Objectives Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. Materials and methods We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib. Results and conclusion Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect